Compare UFI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | PMVP |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.9M | 66.0M |
| IPO Year | N/A | 2020 |
| Metric | UFI | PMVP |
|---|---|---|
| Price | $3.98 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 85.3K | ★ 214.0K |
| Earning Date | 02-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $559,646,000.00 | N/A |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.96 | $0.81 |
| 52 Week High | $6.49 | $1.84 |
| Indicator | UFI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 35.24 |
| Support Level | $3.77 | $1.16 |
| Resistance Level | $3.99 | $1.26 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 85.44 | 13.89 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.